• S1 Episode 4: Managing Lung Cancer With Neoadjuvant and Adjuvant Therapy

  • Oct 13 2022
  • Length: 24 mins
  • Podcast

S1 Episode 4: Managing Lung Cancer With Neoadjuvant and Adjuvant Therapy

  • Summary

  • Drs Jacob Sands and Benjamin Levy discuss the management of lung cancer with neoadjuvant and adjuvant therapy and the potential impact of current clinical trials.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969535). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group https://ascopubs.org/doi/pdf/10.1200/JCO.2007.13.9030

    ADAURA: Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2027071

    Osimertinib: Medscape Drugs & Diseases https://reference.medscape.com/drug/tagrisso-osimertinib-1000062

    Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB–IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02098-5/fulltext

    Atezolizumab: Medscape Drugs & Diseases https://reference.medscape.com/drug/tecentriq-atezolizumab-1000098

    Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext

    Pembrolizumab: Medscape Drugs & Diseases https://reference.medscape.com/drug/keytruda-pembrolizumab-999962

    Pembrolizumab (Pembro) Versus Placebo for Early-Stage Non-Small Cell Lung Cancer (NSCLC) Following Complete Resection and Adjuvant Chemotherapy (Chemo) When Indicated: Randomized, Triple-Blind, Phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Study https://oncologypro.esmo.org/meeting-resources/esmo-virtual-plenary-resources/pearls-keynote-091-pembrolizumab-pembro-versus-placebo-for-early-stage-non-small-cell-lung-cancer-nsclc-following-complete-resection-and-adjuvant-chemotherapy

    Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa2202170

    Nivolumab: Medscape Drugs & Diseases https://reference.medscape.com/drug/opdualag-nivolumab-relatlimab-4000249

    Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial) https://ascopubs.org/doi/full/10.1200/JCO.21.02660

    New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT) https://clinicaltrials.gov/ct2/show/NCT04564157

    Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer https://www.lungcancerresearchfoundation.org/research/lung-cancer-mutation-consortium/current-lcmc-study/

    ALCHEMIST: Adjuvant Targeted Therapy or Immunotherapy for High-Risk Resected NSCLC https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.TPS9077

    Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study https://www.clinicaltrials.gov/ct2/show/NCT04267848

    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about S1 Episode 4: Managing Lung Cancer With Neoadjuvant and Adjuvant Therapy

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.